Address correspondence to Dr Christopher Gibbons, Center for Autonomic and Peripheral Nerve Disorders, Beth Israel Deaconess Medical Center, 1 Deaconess Rd, Palmer 111, Boston, MA 02215, firstname.lastname@example.org.
RELATIONSHIP DISCLOSURE: Dr Gibbons has received personal compensation for serving as a scientific advisor for Theravance Biopharma and Lundbeck and as an associate editor for Autonomic Neuroscience: Basic & Clinical, research/grant support from Grifols, and publishing royalties from UpToDate, Inc. Dr Gibbons has held stock/stock options in Cutaneous Neurodiagnostics, LLC, and has given expert medical testimony. Dr Freeman has received personal compensation and/or stock options for serving on scientific advisory boards of Abide Therapeutics; Applied Therapeutics, Inc; Aptinyx, Inc; Astellas Pharma; Biogen; Biohaven Pharmaceuticals; Chromocell; Cutaneous Neurodiagnostics, LLC; GW Pharmaceuticals, plc; Ironwood Pharmaceuticals; Lundbeck; Mundipharma; NeuroBo Pharmaceuticals; Novartis; Pfizer, Inc; Regenacy Pharmaceuticals; Spinifex Pharmaceuticals; Theravance Biopharma; Toray Medical Co, Ltd; and Vertex Pharmaceuticals. Dr Freeman has received personal compensation for serving as editor-in-chief of Autonomic Neuroscience: Basic & Clinical. Drs Wang, Kim, and Campagnolo report no disclosures.
UNLABELED USE OF PRODUCTS/INVESTIGATIONAL USE DISCLOSURE: Drs Gibbons, Wang, Kim, Campagnolo, and Freeman report no disclosures.